117 Aufrufe 117 0 Kommentare 0 Kommentare

    Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

    Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference being held from September 9-11, 2024 in New York.

    Details of the event are as follows:
    Date: Tuesday, September 10, 2024
    Time: 2:30 p.m. ET

    The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.

    About Adicet Bio, Inc.

    Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.


    The Adicet Bio Stock at the time of publication of the news with a fall of -6,30 % to 1,265EUR on Lang & Schwarz stock exchange (27. August 2024, 22:03 Uhr).


    Business Wire (engl.)
    0 Follower
    Autor folgen

    Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, …